Federal contract award
75A50118C00015
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $49.2M |
| Current contract value | $49.2M |
| Potential contract value / ceiling | $49.2M |
| Start date | Jul 12, 2018 |
| Current end date | Jul 6, 2026 |
| Potential end date | Jul 6, 2026 |
| Latest award activity | Jul 6, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 23 of 23 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 6, 2026 | P00022 | $-537.2K | DEOBLIGATE AND CLOSE OUT THE CONTRACT CLIN 0005 OPTION 4 DECREASED BY $216,710.73 CLIN 0002 OPTION 1 DECREASED BY $320,466.91 TOTAL CONTRACT OBLIGATED AMOUNT DECREASED BY $537,177.64 FROM $65,643,000.14 TO $65,105,822.50. |
| Sep 4, 2025 | P00021 | $-61.9K | MODIFICATION P00021 THIS MODIFICATION IS BEING ISSUED TO DE-OBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $61,887.86. |
| Jul 14, 2025 | P00020 | $0 | MODIFICATION P00020 THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: A) UPDATE ARTICLE G.2. CONTRACTING OFFICER?S REPRESENTATIVE (COR). |
| Jun 17, 2025 | P00019 | $6.4M | MODIFICATION P00019 THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: A) CHANGE ARTICLE F.2. DELIVERABLES, ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR), AND ARTICLES G.5. INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING TO |
| Dec 23, 2024 | P00018 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION P00018 IS TO: A) CHANGE CLIN 0002 OPTION 1?S COST SHARE PORTION TO INCREASE SPERO?S SHARE FROM $161,178.00 BY $96,236.00 TO $257,414.00 WITH THE GOVERNMENT SHARE REMAINING UNCHANGED. B) THIS CHANGE HEREBY |
| Nov 20, 2024 | P00017 | $0 | THE PURPOSE OF THIS BILATERAL MODIFICATION P00017 IS TO: A) CHANGE THE KEY PERSONNEL LISTED IN ARTICLE G.3 KEY PERSONNEL AS FOLLOWS: 1. CHANGE TIMOTHY KEUTZER'S TITLE TO PROGRAM LEAD & CHIEF OPERATING OFFICER. 2. REPLACE EMILY AFSHAR WITH |
| Jul 23, 2024 | P00016 | $0 | MODIFICATION P00016 THE PURPOSE OF THIS UNILATERAL MODIFICATION IS TO: A) CORRECT THE PERIOD OF PERFORMANCE END DATE OF CLIN 0002 TO 12/31/2025 PER THE AGREED CONTRACT TERMS. B) AS A RESULT OF THE FOREGOING, THE US GOVERNMENT SHARE OF THE TOTAL |
| Jul 3, 2024 | P00015 | $11.7M | MODIFICATION P00015 THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: A) INCREASE THE US GOVERNMENT FUNDING FOR CLIN 0005 OPTION 4 FROM $12,498,467 BY $11,697,110 TO $24,195,577 AND THE SPERO COST SHARE FROM $63,204,595 BY $14,683,133 TO $77,887, |
| Dec 20, 2023 | P00014 | $641.6K | ADVANCE THE DEVELOPMENT OF SPR994 AS AN ORAL THERAPY FOR USE IN ADULTS TO TREAT COMPLICATED URINARY TRACT INFECTIONS (CUTIS), INCLUDING THOSE CAUSED BY DRUG RESISTANT BACTERIA |
| Oct 20, 2023 | P00013 | $0 | THIS NO COST BILATERAL MODIFICATION IS FOR A NO COST EXTENSION FOR CLIN 0002. |
| Jul 11, 2023 | P00012 | $0 | THIS NO COST BILATERAL MODIFICATION TO AMEND THE KEY PERSONNEL SECTION WITHIN THE CONTRACT. DR. AKASH JAIN WILL REPLACE ERIN WENZEL AS DIRECTOR ALLIANCE MANAGEMENT. ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED. 2. ADD FAR CLAUSE 52.204-27 PROHIBIT |
| Jan 10, 2023 | P00011 | $0 | THIS MOD IS TO REVISE THE POP FOR CLIN 2 TO REFLECT DEC 31,2023 IN ORDER FOR THE VENDOR TO PROCESS INVOICES IN THE IPP SYSTEM. |
| Oct 25, 2022 | P00010 | $0 | THIS MOD IS TO REVISE SOW FOR CLIN 2 TO REFLECT THE NEW DEVELOPMENT PLAN FOR TEBIPENENEM HBR FOLLOWING FDA FEEDBACK AT THE TYPE A MEETING, AS WELL AS THE COMPLETE RESPONSE LETTER RECEIVED IN JUNE 2022. |
| Sep 28, 2022 | P00009 | $12.5M | THIS MOD SHOULD INCLUDE UPDATED SOW, GO/NO-GO MILESTONES, GANTT CHART) CHANGE THE CO FROM KATHY TO JONATHAN GONZALEZ; CHANGE KEY PERSONNEL CMO FROM DAVID TO KAMAL; REFLECT CHANGES TO IPP SYSTEM FOR INVOICING. |
| Sep 21, 2022 | P00008 | $-12.5M | CHANGE COR |
| Feb 11, 2022 | P00007 | $0 | CHANGE COR |
| Jan 14, 2022 | P00006 | $12.9M | EXERCISE OPTION 3/CLIN0004 |
| Oct 27, 2021 | P00005 | $0 | PROVIDE A NCE THROUGH 12/15/2022; INCORPORATE COVID-19 LANGUAGE; UPDATE SOW |
| May 27, 2021 | P00004 | $0 | CHANGE KEY PERSONNEL AND UPDATE RELATED ARTICLE |
| Nov 3, 2020 | P00003 | $0 | EXERCISE OF OPTION 1 (CLIN 0002) |
| Jan 31, 2020 | P00002 | $0 | EXERCISE OF OPTION 1 (CLIN 0002) |
| May 19, 2019 | P00001 | $2.5M | IGF::OT::IGF |
| Jul 12, 2018 | 0 | $15.7M | IGF::OT::IGF |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.